<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="29c66e31-424a-47af-81e4-492bcf89b062"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Diphenhydramine Hydrochloride Injection, USP</content>
      <br/>
      <content styleCode="bold">Rx only</content>
   </title>
   <effectiveTime value="20250505"/>
   <setId root="d32d074a-f1b6-4a9a-8e10-e19f0e67c61b"/>
   <versionNumber value="15"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="118546603" root="1.3.6.1.4.1.519.1"/>
            <name>Cardinal Health 107, LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2597826e-4e43-4673-be15-35b2da45796b"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250505"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="55154-5102" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Diphenhydramine Hydrochloride</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>diphenhydramine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="0641-0376" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TC2D6JAD40" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIPHENHYDRAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="8GTS82S83M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>DIPHENHYDRAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="ug" value="100"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="PH41D05744" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZETHONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="CNTM">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="CNTM">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="5"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="55154-5102-5" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20110628"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA080817" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20110628"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_c6947ea5-1c86-40e0-933d-d99ccb38670e">
               <id root="40b0e763-6e64-4e84-a787-322c65ec8bb1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Diphenhydramine Hydrochloride Injection is a sterile, nonpyrogenic solution for intravenous or deep intramuscular use as an antihistaminic agent. Each mL contains diphenhydramine hydrochloride 50 mg and benzethonium chloride 100 mcg in Water for Injection. pH 4.0-6.5; sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment.</paragraph>
                  <paragraph>The chemical name of diphenhydramine hydrochloride is 2-(Diphenylmethoxy)-N,N-dimethylethylamine hydrochloride. The structural formula is as follows:</paragraph>
                  <renderMultiMedia ID="id234" referencedObject="MM1"/>
                  <paragraph>C<sub>17</sub>H<sub>21</sub>NO • HCl MW 291.82</paragraph>
                  <paragraph>Diphenhydramine hydrochloride occurs as a white crystalline powder and is freely soluble in water and alcohol.</paragraph>
               </text>
               <effectiveTime value="20210514"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structural formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="diphenhydramine-hydrochloride-injection-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_db190e94-edae-4fb4-845d-8ca74b27560e">
               <id root="937b9abc-c779-4716-8093-255976388323"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.</paragraph>
                  <paragraph>Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of Diphenhydramine Hydrochloride Injection is not available.</paragraph>
               </text>
               <effectiveTime value="20210514"/>
            </section>
         </component>
         <component>
            <section ID="LINK_c7da3956-456b-4466-aee6-694cf34a363d">
               <id root="2543d0d5-b799-4107-89aa-29927d445889"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Diphenhydramine Hydrochloride Injection is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when the oral form is impractical:</paragraph>
               </text>
               <effectiveTime value="20240906"/>
               <component>
                  <section ID="LINK_8605aa18-15b5-4717-a81d-2bda01a27975">
                     <id root="055045de-5b84-4243-9589-3a42612d096c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Antihistaminic</title>
                     <text>
                        <paragraph>For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.</paragraph>
                     </text>
                     <effectiveTime value="20210514"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c8c2ce0f-1d33-4dff-a8fe-0e8b87904f60">
                     <id root="fc86f380-f5fd-44b6-8c26-bd4819bd60c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Motion Sickness</title>
                     <text>
                        <paragraph>For active treatment of motion sickness.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_32ca3e75-b93d-419d-b230-e93c0a6fce5b">
                     <id root="f7624caa-d3d9-4ef2-aeb2-c7a390b74fd3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Antiparkinsonism</title>
                     <text>
                        <paragraph>For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents, mild cases of parkinsonism in other age groups and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cf117a92-4572-4704-b806-5d11ec6f6888">
               <id root="88d4cc82-8c78-45e5-85c3-b76818fab08f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <effectiveTime value="20250505"/>
               <component>
                  <section ID="LINK_c96e87f5-bd33-43f3-af0a-9953d90228ee">
                     <id root="d31c32e4-3249-487c-b7d7-0a6cace18a0e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Use in Neonates or Premature Infants</title>
                     <text>
                        <paragraph>This drug should not be used in neonates or premature infants.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_36821f06-6342-45a5-bd53-44cb53489c7f">
                     <id root="315dfcbf-19a6-4100-b889-d2880e5081b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Use in Nursing Mothers</title>
                     <text>
                        <paragraph>Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0766ab98-6346-4e61-92ff-b51719ef515d">
                     <id root="568987ef-90f4-4833-a87e-f4cf37011cfc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Use as a Local Anesthetic</title>
                     <text>
                        <paragraph>Because of the risk of local necrosis, this drug should not be used as a local anesthetic.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5da1b803-0c74-4c57-842e-b3c6301b30ed">
                     <id root="ecd76664-1023-45b1-9042-ea820f67f0ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Antihistamines are also Contraindicated in the Following Conditions</title>
                     <text>
                        <paragraph>Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_481a4464-6de8-4f95-bf82-572c86455726">
               <id root="c6c1e8e0-ffd0-4d12-8bfc-7d0ffc9dfeab"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy or bladder-neck obstruction.</paragraph>
                  <paragraph>Local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine.</paragraph>
               </text>
               <effectiveTime value="20250505"/>
               <component>
                  <section ID="LINK_7a60beea-9066-423c-ac34-172f73cee514">
                     <id root="11465970-0d72-4798-a308-b6d0c68fdf87"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Use in Pediatric Patients</title>
                     <text>
                        <paragraph>In pediatric patients, especially, antihistamines in <content styleCode="italics">overdosage</content> may cause hallucinations, convulsions or death.</paragraph>
                        <paragraph>As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f254f7dd-44b3-4325-8900-fd8507a92a8f">
                     <id root="6eaaba5f-cf21-4174-b036-b6f052058e26"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Use in the Elderly (approximately 60 years or older)</title>
                     <text>
                        <paragraph>Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_00cefc6c-a79c-44b9-9ff8-68d6de39f632">
               <id root="47937470-adec-474c-aeec-33f8beb31c7b"/>
               <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250505"/>
               <component>
                  <section ID="LINK_0b2c9c77-aafb-46cf-8dd1-7ce135e25e6a">
                     <id root="bab3c648-c008-4ab4-a049-712dd4fe40dd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Diphenhydramine hydrochloride has an atropine-like action and, therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease, including asthma.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_996cfb95-1dcb-4006-be96-540143a43a3b">
                     <id root="9b9be7d5-cf5f-4176-9060-f08c371079bd"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol.</paragraph>
                        <paragraph>Patients should be warned about engaging in activities requiring mental alertness, such as driving a car or operating appliances, machinery, etc.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_aeac3439-07f2-4d42-95da-6a6ae6a3251d">
                     <id root="7d29c611-70ac-4cda-8e03-e8484f7d80f6"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.)</paragraph>
                        <paragraph>MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0924b369-7301-41db-b261-36434ea2cec3">
                     <id root="0679331b-1791-45de-a4bc-1e6937daa845"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_431880ca-0809-4c9a-84bd-5b3622a0d165">
                     <id root="169c6037-3145-4c0d-8d06-d39aa49e49fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20250505"/>
                     <component>
                        <section ID="LINK_317dcb02-a9b0-4dfe-9ee0-948aec7b449e">
                           <id root="88d7a6aa-c57d-47e4-870e-9990ad16552f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic Effects—Pregnancy Category B</content>
                           </title>
                           <text>
                              <paragraph>Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
                           </text>
                           <effectiveTime value="20250505"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4859c100-39e5-4fde-b367-c419b27b7e7e">
                     <id root="02ae93f0-21d9-45c4-bf0b-7e1cd7fbd720"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Diphenhydramine should not be used in neonates and premature infants (see <content styleCode="bold">
                              <linkHtml href="#LINK_cf117a92-4572-4704-b806-5d11ec6f6888">CONTRAINDICATIONS</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Diphenhydramine may diminish mental alertness, or in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions or death (see <content styleCode="bold">
                              <linkHtml href="#LINK_481a4464-6de8-4f95-bf82-572c86455726">WARNINGS</linkHtml>
                           </content> and <content styleCode="bold">
                              <linkHtml href="#LINK_29f1dbb6-f606-4b17-b3d5-af60ee4be5d4">OVERDOSAGE</linkHtml>
                           </content>).</paragraph>
                        <paragraph>See also <content styleCode="bold">
                              <linkHtml href="#LINK_072ff7e8-6470-461a-a2fd-2be3f100a1fa">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content> section.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cd6bae14-a07a-4348-9937-7f60c8e62308">
               <id root="1e901207-9803-47d3-8f37-85a827c7e64b"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The most frequent adverse reactions are italicized.</paragraph>
               </text>
               <effectiveTime value="20250505"/>
               <component>
                  <section ID="LINK_427f1101-be19-4aae-bd77-1689929b10de">
                     <id root="9cafd00d-bd04-4bbe-a5e4-4f44a43697d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Urticaria; drug rash; anaphylactic shock; photosensitivity; excessive perspiration; chills; dryness of mouth, nose and throat.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_24e74d5b-7ce8-4707-b2b8-6cccc09312f1">
                     <id root="7d0dd845-d210-4b4e-a9bb-d93831d9430e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Cardiovascular System</title>
                     <text>
                        <paragraph>Hypotension, headache, palpitations, tachycardia, extrasystoles.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_42663c14-0ce9-4edf-b673-218d25739926">
                     <id root="1c092974-7b52-470d-87c6-99148fafd173"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hematologic System</title>
                     <text>
                        <paragraph>Hemolytic anemia, thrombocytopenia, agranulocytosis.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_90dffa3b-d021-4cc0-8a9d-e4b469ea4b27">
                     <id root="0a07d806-1e1d-4997-8271-8af4133eada1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Nervous System</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Sedation</content>, <content styleCode="italics">sleepiness</content>, <content styleCode="italics">dizziness</content>, <content styleCode="italics">disturbed coordination</content>, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cf9c5870-27fd-4873-be2d-9de498d2e4e1">
                     <id root="9bf55534-9948-4776-991a-f9d7e652359c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Gastrointestinal System</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Epigastric distress</content>, anorexia, nausea, vomiting, diarrhea, constipation.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b2f4c5f6-789f-4b2b-a2af-c10a4402f07e">
                     <id root="15c4a05d-bc17-4995-a5f4-aa5ea6b1ede7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Genitourinary System</title>
                     <text>
                        <paragraph>Urinary frequency, difficult urination, urinary retention, early menses.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9e0f97af-d01d-438b-a4be-eba44a709d01">
                     <id root="89f3a90a-aea8-4b9f-8bf5-6154ad81d901"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Respiratory System</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Thickening of bronchial secretions</content>, tightness of chest and wheezing, nasal stuffiness.</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_29f1dbb6-f606-4b17-b3d5-af60ee4be5d4">
               <id root="156bffec-b8ed-4eba-8502-76d922a25a88"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils; flushing, and gastrointestinal symptoms may also occur.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Stimulants</content> should <content styleCode="bold">not</content> be used.</paragraph>
                  <paragraph>Vasopressors may be used to treat hypotension.</paragraph>
               </text>
               <effectiveTime value="20250505"/>
            </section>
         </component>
         <component>
            <section ID="LINK_072ff7e8-6470-461a-a2fd-2be3f100a1fa">
               <id root="7d632d32-e760-4baf-9a0d-0dd693e3fce6"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY.</paragraph>
                  <paragraph>Diphenhydramine Hydrochloride Injection is indicated when the oral form is impractical.</paragraph>
                  <paragraph>DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.</paragraph>
               </text>
               <effectiveTime value="20250505"/>
               <component>
                  <section ID="LINK_1df5c73d-b1ed-4132-b9c1-08c32f964d24">
                     <id root="835d9cfc-624b-4873-8112-d231718c7e7e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Pediatric Patients, Other Than Premature Infants and Neonates</title>
                     <text>
                        <paragraph>5 mg/kg/24 hours or 150 mg/m<sup>2</sup>/24 hours. Maximum daily dosage is 300 mg. Divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly.</paragraph>
                     </text>
                     <effectiveTime value="20240906"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_04130d9a-8dd8-4ee1-91b0-6e721a5ea070">
                     <id root="bc98908d-2136-43d4-b75b-e769bf092c1c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Adults</title>
                     <text>
                        <paragraph>10 to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly; 100 mg if required; maximum daily dosage is 400 mg.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_034c9ab6-022b-4348-963b-1831fdddae5d">
               <id root="46635e0f-e8d2-4563-92ef-081b58e40994"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Diphenhydramine Hydrochloride Injection, USP 50 mg/mL</paragraph>
                  <paragraph>Overbagged with 5 x 1 mL vials in each bag, NDC 55154-5102-5</paragraph>
                  <paragraph>WARNING: This Unit Dose package is not child resistant and is Intended for Institutional Use Only. Keep this and all drugs out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20250505"/>
               <component>
                  <section ID="LINK_efd3a470-9a81-43df-980b-f2aecc3d66f5">
                     <id root="88768858-2151-4172-bb8e-afc63fd2d3d0"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>Storage</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Protect from light. Keep covered in carton until time of use. Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].</content>
                        </paragraph>
                        <paragraph>To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.<br/> For Product Inquiry call 1-877-845-0689.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Manufactured by:</content>
                           <br/> Hikma Pharmaceuticals USA Inc.<br/> Berkeley Heights, NJ 07922</paragraph>
                        <paragraph>
                           <content styleCode="bold">Distributed By:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardinal Health </content>
                        </paragraph>
                        <paragraph>Dublin, OH 43017</paragraph>
                        <paragraph>L25632450425</paragraph>
                        <paragraph>Revised September 2023<br/>
                           <br/> 462-220-03</paragraph>
                     </text>
                     <effectiveTime value="20250505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7053f861-3317-4c0e-bd2f-81823427853f">
               <id root="4e10c92a-f5a8-43b1-b985-65fbfb1799ac"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel </title>
               <text>
                  <paragraph>NDC 55154-5102-5</paragraph>
                  <paragraph>
                     <content styleCode="bold">DiphenhyrAMINE HCl</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">INJECTION, USP 50 mg/mL</content>
                  </paragraph>
                  <paragraph>HIGH POTENCY</paragraph>
                  <paragraph>5 x 1 mL VIALS</paragraph>
                  <renderMultiMedia ID="id-1887090808" referencedObject="ID_83c06108-c025-4880-9716-d58848d0fb64"/>
               </text>
               <effectiveTime value="20250505"/>
               <component>
                  <observationMedia ID="ID_83c06108-c025-4880-9716-d58848d0fb64">
                     <text>50mg/mL bag label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="a26a0df5-fdb8-4c50-ac01-8ae033578bf0-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>